Danaher, a global science and technology company, headquartered in Washington D.C., has completed its $21.4-billion acquisition of the biopharma business from General Electric’s Life Sciences division. As part of Danaher, the business will be called Cytiva and will be a standalone operating company within Danaher’s Life Sciences segment. The companies had announced the acquisition in February 2019.

Cytiva, previously GE Healthcare Life Sciences, has nearly 7,000 employees and operations in 40 countries with sales of approximately $3.3 billion. Cytiva is a provider of instruments, consumables, and software that support the research, discovery, process development and manufacturing workflows of biopharmaceuticals. The business is comprised of process chromatography hardware and consumables, cell-culture media, single-use technologies, development instrumentation and consumables, and services.

Pharmaceutical Diagnostics remains part of the GE Healthcare portfolio. This business supplies contrast media and molecular imaging consumables for radiology customers around the world and is highly complementary to GE Healthcare’s medical imaging business. GE’s pharmaceutical imaging agents are used in approximately 90 million patient procedures each year. 

Source: Danaher and Cytiva